Senti Biosciences, Inc. ( (SNTI) ) has released its Q3 earnings. Here is a breakdown of the information Senti Biosciences, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, targeting challenging liquid and solid tumor indications.
Senti Bio has reported its financial results for the third quarter of 2025, highlighting significant progress in its SENTI-202 study for Acute Myeloid Leukemia (AML). The company is set to present updated clinical data at the upcoming American Society of Hematology Annual Meeting in December, showcasing the efficacy and safety of its innovative treatments.
Key financial metrics from the third quarter include a net loss of $18.1 million, or $0.69 per share, with research and development expenses rising to $10.5 million. The company’s cash and cash equivalents stood at $12.2 million as of September 30, 2025, a decrease from $48.3 million at the end of 2024. Senti Bio continues to engage with the investor and scientific communities through various conferences and webinars to build market awareness.
Looking ahead, Senti Biosciences remains focused on advancing its clinical trials and expanding its dataset for SENTI-202, with the aim of achieving selective cancer targeting while sparing healthy tissues. The company is committed to leveraging its Gene Circuit platform to develop innovative therapies for incurable diseases, with ongoing efforts to enhance its capabilities through strategic partnerships.